Atreca, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-09-27: Reporting owner Ruiz Roger Richard; Form 3; Security Employee stock option (right to buy); Transaction Holding.
- 2023-09-27: Reporting owner Ruiz Roger Richard; Form 3; Security Employee stock option (right to buy); Transaction Holding.
- 2023-09-27: Reporting owner Ruiz Roger Richard; Form 3; Security Employee stock option (right to buy); Transaction Holding.
- 2023-09-27: Reporting owner Ruiz Roger Richard; Form 3; Security Employee stock option (right to buy); Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-09-27 holding as of filing | Ruiz Roger Richard Officer (VP of Finance) | 3 | Employee stock option (right to buy) Derivative · Direct | Holding | $3.18 exercise price | 2023-09-27 | ||
| 2023-09-27 holding as of filing | Ruiz Roger Richard Officer (VP of Finance) | 3 | Employee stock option (right to buy) Derivative · Direct | Holding | $1.85 exercise price | 2023-09-27 | ||
| 2023-09-27 holding as of filing | Ruiz Roger Richard Officer (VP of Finance) | 3 | Employee stock option (right to buy) Derivative · Direct | Holding | $1.49 exercise price | 2023-09-27 | ||
| 2023-09-27 holding as of filing | Ruiz Roger Richard Officer (VP of Finance) | 3 | Employee stock option (right to buy) Derivative · Direct | Holding | $1.85 exercise price | 2023-09-27 | ||
| 2023-09-27 holding as of filing | Ruiz Roger Richard Officer (VP of Finance) | 3 | Employee stock option (right to buy) Derivative · Direct | Holding | $1.85 exercise price | 2023-09-27 | ||
| 2023-09-27 holding as of filing | Ruiz Roger Richard Officer (VP of Finance) | 3 | Employee stock option (right to buy) Derivative · Direct | Holding | $1.85 exercise price | 2023-09-27 | ||
| 2023-06-13 | Rolfe Lindsey Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-06-13 | Robinson William Hewitt Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-06-13 | Ma Stacey Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-06-13 | Lacey David L. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-06-13 | Brady Stephen R Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-06-13 | BERGER FRANKLIN M Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-06-13 | BALL KRISTINE M Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-06-13 | ATWOOD BRIAN G Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $1.18 exercise price | 2023-06-15 | |
| 2023-02-09 | Orwin John A Director, Officer (President & CEO) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +435,000 435,000 owned after | $1.49 exercise price | 2023-02-13 | |
| 2023-02-09 | CROSS HERB Officer (Chief Financial Officer) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +175,000 175,000 owned after | $1.49 exercise price | 2023-02-13 | |
| 2023-02-09 | Serafini Tito Director, Officer (Chief Strategy Officer) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +175,000 175,000 owned after | $1.49 exercise price | 2023-02-13 | |
| 2023-02-09 | Courtney Phillips Officer (General Counsel & Secretary) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,000 130,000 owned after | $1.49 exercise price | 2023-02-13 | |
| 2023-02-09 | Gould Stephen E Officer (Chief Scientific Officer) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,000 130,000 owned after | $1.49 exercise price | 2023-02-13 | |
| 2023-01-09 | Bishop Philippe C Officer (Chief Medical Officer) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +350,000 350,000 owned after | $1.37 exercise price | 2023-01-11 |